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ABSTRACT Objective: Despite  recent  advancements  in  targeted  therapy  and immunotherapies,  prognosis  for  metastatic  melanoma patients
remains  extremely  poor.  Development  of  resistance  to  previously  effective  treatments  presents  a  serious  challenge  and  new
approaches for melanoma treatment are urgently needed. The objective of this study was to examine the effects of telmisartan, an
AGTR1 inhibitor and a partial agonist of PPARγ, on melanoma cells as a potential agent for repurposing in melanoma treatment.
Methods: Expression  of  AGTR1  and  PPARγ mRNA  in  melanoma  patient  tumor  samples  was  examined  in  publicly  available
datasets and confirmed in melanoma cell lines by qRT-PCR. A panel of melanoma cell lines was tested in viability, apoptosis and
metabolic assays in presence of telmisartan by flow cytometry and immunocytochemistry.  A cytotoxic effect  of  combinations of
telmisartan and targeted therapy vemurafenib was examined using the Chou-Talalay combination index method.
Results: Both  AGTR1  and  PPARγ mRNA  were  expressed  in  melanoma  patient  tumor  samples  and  decreased  compared  to  the
expression in  the  healthy  skin. In  vitro,  we  found that  telmisartan decreased melanoma cell  viability  by  inducing  cell  apoptosis.
Increased  glucose  uptake,  but  not  utilization,  in  the  presence  of  telmisartan  caused  the  fission  of  mitochondria  and  release  of
reactive  oxygen  species.  Telmisartan  altered  the  cell  bioenergetics,  thereby  synergizing  with  vemurafenib in  vitro,  and  even
sensitized vemurafenib-resistant cells to the treatment.
Conclusions: Given  that  the  effective  doses  of  telmisartan  examined  in  our  study  can  be  administered  to  patients  and  that
telmisartan is a widely used and safe antihypertensive drug, our findings provide the scientific rationale for testing its efficacy in
treatment of melanoma progression.
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Introduction
Melanoma is one of the most aggressive malignancies. If left
untreated,  patients  with  distant  metastasis  have  a  median
survival  of  6–9  months.  In  the  last  decade,  a  dramatic
improvement in the survival of melanoma patients has been
achieved  with  neutralizing  antibodies  targeting  immune
checkpoints  (anti-PD-1  and  anti-CTLA-4  immunotherapy)
and via  targeted  BRAF  and  MEK  inhibition1.  However,
mortality rates remain high in advanced-stage patients2. Fifty
percent  of  melanoma  tumors  carry  the  BRAF  V600E
mutation,  but  despite  the  dramatic  initial  effects  of  BRAF
inhibitors  in  clinical  settings,  patients  eventually  experience
relapse,  suggesting  that  combination  therapies  may  be
needed to overcome resistance. In most developed countries,
patients  with  BRAF-mutated  melanoma  receive  a
combination  of  BRAF  and  MEK  inhibitor  therapies,  which
has  high  response  rates;  nevertheless,  the  median  time  to
relapse  is  less  than  10  months3.  Both  genetic  and  epigenetic
changes  contribute  to  the  resistance  to  targeted  therapy.
Better  understanding  of  the  mechanisms  of  resistance  is
needed  as  well  as  strategies  to  overcome  them.  BRAF
inhibitors suppress glycolysis4, yet the subsequent increase in
oxidative metabolism limits  their  efficacy5.  Many melanoma
driver  genes  control  cellular  metabolism.  Heterogeneity  in
genetic  driver  profiles  and  mitochondrial  capacity  can
influence  the  effectiveness  of  the  treatment6.  Therefore,
agents  that  target  different  aspects  of  cell  metabolism  could
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Development of new drugs is costly, and the approval for
their use and translation into clinics often takes between 10
and  15  years.  In  contrast,  repurposing  of  drugs  already
approved  for  other  uses  (drugs  that  have  been  tested  in
humans ,  and  for  which  in format ion  regard ing
pharmacology,  formulation,  and  potential  toxicity  is
available) enables their quick translation into clinical trials
and  integration  into  healthcare7.  Recently,  it  has  been
recognized that  therapy  for  chronic  diseases  can have  an
impact on the progression and outcome in cancer patients. In
this  study,  we  examined  the  effects  of  telmisartan  on
melanoma cells.  Telmisartan is  an angiotensin receptor 1
(AGTR1)  inhibitor  and  a  partial  agonist  of  peroxisome
proliferator-activated  receptor  γ  (PPARγ).  Human
melanoma tissues express both angiotensin II and AGTR1,
and inhibition of AGTR1 in mouse models of melanoma was
shown to  inhibit  tumor  growth  by  decreasing  the  tumor
vessel  density8.  PPARγ  is  a  nuclear  receptor  that  is  an
important  regulator  of  lipid  and  glucose  metabolism9.
Activation  of  PPARγ  in  melanoma  cells  has  growth-
inhibitory effects10,11  via  the induction of cell  cycle arrest.
PPARγ agonists have also been shown to have pro-apoptotic
PPARγ-independent effects12. In recent years, telmisartan has
been reported to have anticancer effects in in vitro and in vivo
models  of  various  solid  tumors13-17,  but  its  effects  on
melanoma have  not  yet  been  investigated.  Therefore,  we
hypothesized that telmisartan through its dual activity, as an
AGTR1 inhibitor and PPARγ  agonist  with possible extra-
receptor effects, can have an anti-melanoma activity that is
superior to that of agents with single activity. In this study,
we have found that telmisartan induces apoptosis in both
BRAF V600E mutated and wild-type melanoma cells,  and
that  it  causes  mitochondrial  fragmentation  and  the
generation  of  free  radicals.  The  alteration  of  cellular
energetics  by telmisartan enabled it  to  synergize  with the
BRAF  inhibitor  vemurafenib,  thereby  improving  the
response  in  a  vemurafenib-resistant  melanoma  cell  line.
Collectively,  we  report  that  the  clinically  available
antihypertensive  agent  telmisartan  can  potentially  be
repurposed  as  an  anti-cancer  therapeutic  for  melanoma
treatment.
Materials and methods
In silico gene expression analysis
For  the  analysis  of PPARγ  and  AGTR1  expression  in
melanoma  tumors,  the  datasets  GSE7553,  GSE19234,
GSE3189, GSE46517, and GSE8401 were uploaded to GEO2R
(https://www.ncbi.nlm.nih.gov/geo/geo2r/),  and  the  samples
were  divided  into  the  following  groups:  normal  skin,
melanoma in  situ,  primary  melanoma,  and  metastatic
melanoma.  Sample  values  were  plotted  in  Prism  7
(Graphpad)  and  analyzed  using  one-way  ANOVA  and
Dunnett's multiple comparisons test. For the survival analysis
of data from the GSE19234 dataset, the samples were divided
into the PPARγ-high and PPARγ-low expression groups (the
2  ×  SD  value  was  used  for  determining  the  cut-off)  and
analyzed using the log-rank (Mantel-Cox) test.
Cell culture, drug treatments and viability
assays
Human melanoma cell lines with the BRAF V600E mutation
A375 and 518a2 and the BRAF wild-type melanoma cell lines
HTB140 and FemX-1 were  cultured  in  RPMI 1640  medium
with  2  g/L  glucose  (Sigma-Aldrich,  R8755,  Taufkirchen,
Germany), 10% FBS, and antibiotics. The A375 cell  line was
procured from ATCC. The FemX-1 cell line18 was a kind gift
from Dr Nikola Vujanović. The 518a2 and HTB140 cell lines
were  kind  gifts  from  Dr  Milica  Pešić.  All  the  cell  lines  were
tested  for  the  presence  of  mycoplasma  by  PCR19,  and  if
required,  treated  with  MycoXpert  (Capricorn  Scientific,
Ebsdorfergrund,  Germany).  Vemurafenib  (Zelboraf),
telmisartan,  pioglitazone,  and  losartan-potassium  were
provided  by  the  Medicines  and  Medical  Devices  Agency  of
Serbia as pure substances. N-acetyl-L-cysteine, L-glutathione,
2-deoxy-D-glucose,  and  apocynin  were  obtained  from
Sigma-Aldrich. The cytotoxicity of the drugs was determined
by  performing  the  MTT  assay  (Sigma-Aldrich)  in  96-well
plates,  at  a  density  of  5,000  cells/well,  with  at  least  three
biological  repeats.  After  72  h  of  incubation  with  the  drugs,
the absorbance of the samples was measured at 570 nm on a
Multiskan  EX  reader  (Thermo  Labsystems,  Helsinki,
Finland).  IC50 values  (μM) were  determined from the  dose-
response  curves  as  the  concentration  of  the  compound
causing a 50% decrease in MTT reduction, compared to the
control (DMSO)-treated samples.
Annexin/PI assay
Quantitative  analysis  of  apoptotic  and  necrotic  cell  death
induced by  50  μM telmisartan  or  100  μM  pioglitazone  was
performed using an Annexin V-FITC apoptosis detection kit,
according  to  the  manufacturer’s  instructions  (BD
Biosciences,  Franklin  Lakes,  USA).  After  24  or  48  h  of
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treatment  with  the  drugs,  the  A375  cells  were  trypsinized,
washed twice  with ice-cold PBS,  and resuspended in 200 μL
of  binding  buffer[10  mM HEPES/NaOH (pH 7.4),  140  mM
NaCl,  2.5  mM CaCl2].  Next,  2  × 10
5 cells  were  stained with
Annexin V-FITC and PI. After 15 min of incubation at room
temperature in the dark, the cells were analyzed using a FACS
Calibur  Becton  Dickinson  (San  Jose,  USA)  flow  cytometer
and the Cell Quest computer software.
Cell cycle analysis
A375 and  A375R  cells  were  treated  for  72  h  with  0.5  μM
vemurafenib, and quantitative analysis of the cell cycle phase
distribution  was  performed  by  flow  cytometry  (Calibur
Becton  Dickinson  flow  cytometer  and  BD  Cell  Quest
computer  software).  The  DNA  content  in  fixed,  RNaseA  (1
mg/mL)-treated  cells  was  stained  with  400  mg/mL
propidium iodide (PI), and 20,000 events were counted.
Flow cytometric analysis of phospho-p38 and
cleaved caspase 3
After  24  h  (for  phospho-p38)  or  48  h  of  treatment  (for
cleaved caspase  3)  with  50  μ M  telmisartan,  the  cells  were
trypsinized,  fixed,  permeabilized,  and  then  blocked  with
1.5% BSA in PBS. Cells were then incubated with PE mouse
anti-p38MAPK  pT180/pY182  (612565,  BD  Biosciences,
Franklin  Lakes,  USA)  antibody  or  FITC  rabbit  anti-active
caspase-3  antibody  (51-68654x,  BD  Biosciences)  for  1  h  in
the  dark  at  room temperature.  After  washing,  the  cells  were
resuspended  in  PBS  and  analyzed  using  a  FACS  Calibur
Becton Dickinson flow cytometer.
Detection of intracellular ROS and
mitochondrial potential
For the detection of ROS, 2 × 105 A375 or HTB140 cells were
treated with  50  μ M telmisartan,  100  μ M  pioglitazone,
100 μM losartan,  or  50  μM telmisartan  in  the  presence  of  1
mM L-GSH, 10 mM NAC, or 100 μM apocynin for 24 h. The
cells were  stained  with  50  μM  H2DCFDA  (D3999,  Thermo
Fischer  Scientific,  Schwerte,  Germany)  for  30  minutes  at
37°C.  For  the  measurement  of  the  mitochondrial  potential,
A375 cells  were  treated  with  50  μM telmisartan  or  100  μM
pioglitazone for  24  h,  and  then  stained  with  2.5  μ g/mL  of
Rhodamine123 (R302, Thermo Fischer Scientific) in PBS for
1  h  at  37°C,  and  analyzed  using  a  FACS  Calibur  Becton
Dickinson flow cytometer.
Glucose uptake and consumption and lactate
production
Glucose uptake was measured by flow cytometry as described
in a previous report20. A375 cells were pretreated for 1 or 24 h
with 50 μM telmisartan or 50 μM pioglitazone and incubated
with 20 μM 2-NBDG, a fluorescent glucose analog (N13195,
Thermo Fischer Scientific), for 1 h at 37°C.
For measuring the glucose consumption, 10 × 105 A375 or
HTB140 cells were seeded into six-well plates in duplicate.
After 24 h, the cells were collected (from duplicate wells) for
protein extraction at the 0 h time point, and the cells in the
test wells were treated with 50 μM telmisartan or pioglitazone
in  RPMI 1640  medium containing  2  g/L  glucose  (Sigma,
R8755, Taufkirchen, Germany). After 24 h, the medium was
collected and glucose concentration was measured using a
Cobas bioanalyzer C111 (Roche, USA). The remaining cells
were collected for protein extraction at the 24 h time point.
The protein content in the cells was extracted using RIPA
buffer, and the protein concentration was measured using the
Qubit  Fluorometer  and Qubit  Protein assay  kit  (Q33211,
Molecular Probes, Eugene, USA). Glucose consumption was
calculated by subtracting the amount of glucose present in
the medium after 24 h of incubation from the amount of
glucose  initially  present  in  the  medium  (2  g/L),  and
normalized to the area under the curve for cell growth per
hour.  The  experiment  was  repeated  thrice  and  statistical
analysis was performed using two-way ANOVA and Tukey's
multiple comparisons test.
Lactate consumption was measured using an extracellular
acidification assay kit (ab197244, Abcam, Cambridge, UK),
according  to  the  manufacturer’s  instructions.  A375  or
HTB140  cells  were  treated  with  50  μM  telmisartan  or
pioglitazone for 24 h and then trypsinized; equal numbers of
cells were resuspended in 100 μL of resuspension buffer. The
cell suspensions were loaded into 96-well black polystyrene
plates  (237105,  Nunc,  Schwerte,  Germany),  and 10 μL of
Glycolysis  Assay  reagent  was  added  to  each  sample.
Respiration  buffer  plus  the  reagent  served  as  the  blank
control.  Signals  were  measured  at  2-min  intervals  for
120 minutes with an Ex/Em of 380/615 using a Tecan Infinite
m1000Pro reader (Tecan, Zurich, Switzerland) in Dual TR-F
mode with a 30 μs delay and 100 μs gate time. Blank control-
corrected intensity values (AU) were plotted against time in
minutes. The experiment was repeated twice.
Immunocytochemistry for TOM20 and
MitoTracker Red CMXRos staining
Formaldehyde-fixed  melanoma  cells  were  stained  with
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mouse  anti-Tom20  antibody  (F-10,  sc-17764,  Santa  Cruz
biotechnology,  Heidelberg,  Germany)  and  Alexa  Fluor
488  goat  anti-mouse  antibody  (R37120,  Thermo  Fischer
Scientific),  counterstained  with  DAPI  (Sigma),  and
imaged  using  an  epi-fluorescent  microscope  (Olympus,
Japan)  with  a  60  ×  lens.  For  staining  of  the  active
mitochondria, the melanoma cells were stained with 100 nM
MitoTracker Red CMXRos (#9082, Cell Signaling Technology,
Frankfurt,  Germany)  for  20  minutes  at  37°C,  fixed  with
ice-cold  methanol,  and  imaged  using  an  epi-fluorescent
microscope.
Analysis of gene expression by real-time PCR
RNA  was  isolated  from  melanoma  cells  using  the  TRI
REAGENT®  BD  kit  (Sigma-Aldrich).  cDNA  synthesis  from
total RNA (2 μg) was performed using random primers and
MultiScribeTM Reverse Transcriptase from the High-Capacity
cDNA  Reverse  Transcription  kit  (50  U/μL,  Applied
Biosystems,  Schwerte,  Germany).  RT-PCR  was  performed
with  Maxima SYBR green/ROX qPCR master  Mix  (K00221,
Thermo Scientific). The primers used were as follows: PPARγ
forward 5′-GGCTTCATGACAAGGGAGTTTC-3′ and PPARγ
reverse  5′-AACTCAAACTTGGGCTCCATAAAG-3′;  Agtr1
forward  5′-AACAGCTTGGTGGTGATCGTC-3′ and  Agtr1
reverse 5′-CATAGCGGTATAGACAGCCCA-3′. The reactions
were  performed  using  the  ABI  Prism  7,700  Sequence
Detection System (Applied Biosystems). The expression level
data  were  normalized  to  glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH) expression,  analyzed  by  the  delta-
delta-Ct  method,  and  represented  as  the  means  ±  SEMs  of
three independent experiments.
Drug interaction analysis
To determine the synergistic, additive, or antagonistic effects
of  the  drug  combinations,  we  performed  the  combination
index  method  described  by  Chou  and  Talalay21,  using  the
CalcuSyn  software  (version  2.0  Biosoft,  Cambridge,  UK).
This method takes into account both the potency of the drug
[median dose (Dm) or IC50] and the shape of the dose-effect
curve (the m value) to calculate the combination index (CI).
A CI  equal  to  1  indicates  an additive  effect;  a  CI  less  than 1
indicates  synergy.  With  the  use  of  the  CalcuSyn  software,
synergy is further refined as synergism (CI = 0.3–0.7), strong
synergism  (CI  =  0.1–0.3),  and  very  strong  synergism  (CI  <
0.1).  Isobolograms  and  heat  maps  were  plotted  using  the
Prism 7 software.
Results
Expression of PPARγ and AGTR1 receptors in
melanoma patient samples and melanoma cell
lines
We first  performed an in  silico analysis  of  the available  gene
expression  databases  of  melanoma  tumors  in  the  GEO
repository  for  the  expression  of  two  telmisartan  receptors:
PPARγ and  AGTR1 .  We  examined  the  Talantov22,
Kabbarah23,  Riker24,  Xu25,  and Bogunovic26 datasets  (Figure
1). PPARγ  mRNA  expression  was  decreased  in  primary
melanoma,  compared  to  the  uninvolved  skin  (Figure  1A,
1C),  while  there  was  no  difference  between  the PPARγ
mRNA expression in  primary tumors  and metastatic  lesions
(Figure 1B-1D). In the Bogunovic data set26, which includes
the  clinical  outcome  data  for  metastatic  patients,  we  found
that  there  were  very  few  tumors  expressing  high PPARγ
levels, and they were associated with better survival (log-rank
value  not  available  due  to  small  sample  size  in  the PPARγ-
high  expression  group, Figure  1E and  1F).  AGTR1  mRNA
expression  also  decreased  in  primary  tumors,  compared  to
uninvolved  skin  (Figure  2A and  2B ).  Additionally,  in  some
data  sets,  it  further  decreased  in  metastatic  lesions  (Figure
2C),  while  in  others,  there  was  no  difference  between  the
AGTR1 mRNA expression  in  primary  and  metastatic  tumor
samples  (Figure  2B and  2D ).  In  the  Bogunovic  data  set26,
only  3 AGTR1  mRNA  values  were  outside  of  the  standard
deviation  range;  hence,  the  survival  analysis  was  not
performed  (Figure  2E).  Therefore,  there  is  a  trend  of
decrease  in  case  of  both  the PPARγ  and  AGTR1  mRNA
expression  with  the  progression  of  melanoma.  We  then
screened  the  mRNA  expression  of PPARγ  and  AGTR1  in  a
panel  of  four  human  melanoma  cell  lines:  A375,  518a2,
HTB140, and Fem-X. Expression of PPARγ  (Figure 1G) and
AGTR1 mRNA  (Figure  2F)  was  normalized  to GAPDH
expression and was detectable in both the BRAF WT cell lines
(FemX-1  and  HTB140)  and  BRAF  V600E  mutant  cell  lines
(A375  and  518a2).  The  FemX-1  cell  line  showed  the  lowest
expression  of  both  genes,  while  518a2  showed  the  highest
expression.
Telmisartan reduces melanoma cell viability
through the induction of apoptosis
Next, we examined the melanoma cell viability in vitro in the
presence  of  telmisartan  and  compared  it  with  that  observed
after  treatment  with  the  PPARγ agonist  pioglitazone  and
AGTR1 inhibitor losartan. Melanoma cells were treated with
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increasing  concentrations  of  the  drugs  for  72  h,  and  their
viability  was  measured  by  the  MTT  assay  (Figure  3A-3C).
Telmisartan  dose-dependently  reduced  melanoma  cell
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Figure 1   Expression of PPARγ receptor in melanoma. Relative expression levels of PPARγ in melanoma tumors included in (A) GSE318922,
(B) GSE4651723, (C) GSE755324 and (D) GSE840125 datasets. Values represent mean ± SD, * P < 0.05, ** P < 0.01, ***P < 0.001, ****P <
0.0001, One-way ANOVA with Dunett’s multiple comparisons test. (E) High and low PPARγ expression in metastatic melanoma from dataset
GSE1923426, ****P < 0.0001, unpaired t test. (F) Survival curves for 36 metastatic melanoma patients with tumors expressing highest (n = 5)
and lowest (n  = 31) PPARγ levels calculated using Kaplan-Meier analysis. (G) Relative mRNA levels of PPARγ in melanoma cell lines
measured by qRT-PCR. Values represent mean ± SEM of three independent experiments.
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that of pioglitazone at the same concentration in all the tested
cell  lines.  On  the  contrary,  the  direct  AGTR1  antagonist
losartan did not show significant effects (best-fit IC50 values;
Figure  3D).  Interestingly,  cells  with  the  BRAF  V600E
mutation  (A375  and  518a2  cells)  had  lower  IC50 values  for
telmisartan  than  BRAF  WT  cells  (FemX-1  and  HTB140)
(Figure  3A, P  <  0.0001  by  two-way  ANOVA).  We  next
examined the  apoptosis  in  A375  cells  treated  with  50  μM
(IC50)  telmisartan  and  compared  these  results  with  those
obtained after  treatment  with  100  μM (> IC50)  pioglitazone
using the Annexin V/PI assay. Telmisartan increased both the
early-apoptotic  and  late-apoptotic/necrotic  fraction  of  the
cells in a time-dependent manner, while pioglitazone showed
no  significant  effects  (representative  graphs  after  48  h  of
treatment; Figure  3E and  quantification  after  24  and  48  h
Figure  3F).  Apoptosis  was  further  confirmed  by  the
measurement  of  a  significantly  increased  percentage  of
cleaved  caspase  3-positive  cells  by  flow cytometry  after  48  h
of treatment with 50 μM telmisartan (Figure 3G).
Telmisartan induces generation of the reactive
oxygen species (ROS) in melanoma cells
To  examine  the  mode  of  apoptotic  cell  death,  we  first
measured ROS generation after 24 h of telmisartan treatment


























































































































Figure 2   Expression of AGTR1 receptor in melanoma. Relative expression levels of AGTR1 in melanoma tumors included in (A) GSE318922,
(B) GSE4651723, (C) GSE755324 and (D) GSE840125 datasets. Values represent mean ± SD, * P < 0.05, ** P < 0.01, ***P < 0.001, ****P <
0.0001,  One-way ANOVA with Dunett’s  multiple  comparisons test.  (E)  Expression of  AGTR1 in  metastatic  melanoma from dataset
GSE1923426, red marks for values above standard deviation range. (F) Relative mRNA levels of AGTR1 in melanoma cell lines measured by
qRT-PCR. Values represent mean ± SEM of three independent experiments.




































































































































100 101 102 103 104





































Figure 3   Telmisartan reduces melanoma cell viability. Percent viability of melanoma cell lines after 72 h treatment with (A) telmisartan, (B)
pioglitazone and (C) losartan determined by the MTT assay presented as log (inhibitor) vs. no. rmalized response and (D) best-fit IC50 values
for each line, n = 4. (E) Representative graphs and (F) quantification of Annexin/PI assay for apoptosis in A375 cells after 24 h and 48 h of
treatment with 50 μM telmisartan or 100 μM pioglitazone, values represent mean ± SD, ** P < 0.01, Two-way ANOVA, n = 3. (G) Flow
cytometric analysis of cleaved caspase 3 in A375 cells after 48 h treatment with 50 μM telmisartan. Values represent mean ± SD, ***P <
0.001, unpaired t-test, n = 3.
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fluorogenic  dye  that  measures  hydroxyl  radicals,  peroxyl
radicals,  and  other  ROS.  Unlike  pioglitazone  or  losartan,
which at  the  concentration  of  100  μM  did  not  increase  the
oxidation of DCFDA to fluorescent DCF, 50 μM telmisartan
increased  the  relative  ROS  levels  in  A375  cells,  as  measured
by  flow  cytometry  (representative  graph Figure  4A and
quantification Figure  4B).  Consistent  with  this  finding,
telmisartan also increased the levels of phosphorylated p38, a
free radical sensor27, 28 (Figure 4C). NADPH oxidase (NOX)
and oxidative reactions on the mitochondrial membrane are
the main sources of ROS. To examine the potential sources of
ROS  in  telmisartan-treated  cells,  we  measured  the
telmisartan-induced DCFDA fluorescence in the presence of
reduced  glutathione  (L-GSH),  N-actetyl-L-cysteine
(synthetic  precursor  of  GSH  and  cysteine,  free  radical
scavenger), or apocynin (NADPH oxidase inhibitor). While 1
mM L-GSH or 10 mM NAC decreased the relative ROS levels
in the  telmisartan-treated  cells,  100  μ M  apocynin  did  not
prevent  ROS  generation  (Figure  4D).  These  results  imply
that  NADPH-dependent  oxidases  are  not  involved  in
telmisartan-induced  ROS  generation,  and  that  the  ROS
generation  is  of  mitochondrial  origin.  We  confirmed  the
induction  of  ROS  generation  by  telmisartan  and  its
prevention  by  NAC  in  the  BRAF  WT  melanoma  cell  line
HTB140  (Figure  4E).  A  strong  positive  correlation  exists
between  mitochondrial  ROS  release  and  mitochondrial
membrane potential  (ΔΨ)29;  therefore,  we measured the ΔΨ
by  the  flow  cytometry  analysis  of  Rhodamine123-stained
cells.  In  telmisartan-treated  A375  cells,  the  mitochondria
were  hyperpolarized,  as  seen  by  the  loss  of  fluorescence,
unlike the cells treated with pioglitazone, where pioglitazone
had a limited effect on membrane potential even at a higher
dose (Figure 4F).
Telmisartan alters melanoma cell bioenergetics
High  glycolytic  activity  or  impaired  oxidative
phosphorylation  (OXPHOS)  are  possible  sources  of
increased cellular ROS levels30. PPARγ is involved in glucose
sensing31,  and  the  PPARγ agonist  pioglitazone  exerts  its
antidiabetic  activity  by  increasing  the  cellular  glucose
uptake32.  We  measured  whether  telmisartan  too  can  affect
glucose uptake in A375 cells, by measuring the uptake of the
fluorescent glucose analogue 2-NBDG using flow cytometry.
We observed  that  50  μM  telmisartan  significantly  increased
the  2-NBDG uptake  to  a  greater  extent  than  pioglitazone  at
the  same  concentration,  both  shortly  after  its  addition
(measured at the 1 h time point) and after 24 h of treatment
(Figure  5Ai representative  graphs  and 5Aii  quantification).
Next,  we  measured  the  glycolytic  rate  by  examining  the
glucose  consumption  and  lactate  production  in  A375  and
HTB140 cells.  As  expected,  treatment  with  50  μM
pioglitazone  increased  the  glycolysis  in  A375  cells33.  We
observed an  increase  in  glucose  consumption  per  μg  of  cell
protein  (Figure  5B)  and  increased  lactate  production,
measured  by  the  decreased  pH  of  the  culture  medium
(Figure  5C). On  the  contrary,  50  μM  telmisartan  decreased
the glucose consumption and did not change the extracellular
acidification in  A375 cells  (Figure  5B and 5C).  This  implies
that  in  A375  cells,  in  the  presence  of  telmisartan,  glucose  is
taken up at a higher rate, but is not utilized at a higher rate.
To determine whether the decreased consumption of glucose
was  the  cause  for  the  decreased  cell  viability,  we  tested  the
effects  of  telmisartan  in  A375  cells  in  the  presence  of  excess
glucose (25 mM, compared to 11 mM in standard RPMI) or
in  the  presence  of  2-deoxy-D-glucose  (2DG),  a  glycolysis
inhibitor. Increased glucose concentration did not ameliorate
the  effects  of  telmisartan  (Figure  5D),  but  as  expected,  it
ameliorated the effects of 2DG on cell viability. Furthermore,
telmisartan had additive effects with 2DG, as observed in the
MTT  assay  (Figure  5D).  In  HTB140  cells,  at  a  telmisartan
concentration of 50 μM, a similar trend was observed in the
glucose consumption and lactate excretion assays (Figure 5E
and 5F), but statistical significance was not observed. This is
consistent  with  the  observation  of  cytotoxic  effects  in
HTB140  cells,  which  required  higher  doses  of  telmisartan
(Figure  3A and  3D ).  Moreover,  the  basal  level  of  glucose
consumption  was  also  lower  in  HTB140  cells  than  in  A375
cells  (Figure  5B and  E ).  Given  that  increased  intracellular
glucose  uptake  can  induce  mitochondrial  fragmentation34
that  is  causal  for  ROS  production35,  we  examined  the
mitochondrial  morphology  in  A375  and  HTB140  cells  after
telmisartan  treatment  by  the  immunocytochemical  analysis
of  the  mitochondrial  import  receptor  subunit  TOM20.
Treatment with 50 μM telmisartan, but not pioglitazone, for
24 h induced the fragmentation of mitochondria,  as seen by
the  generation  of  mitospheres  (Figure  6A).  We  confirmed
mitochondrial  fragmentation  in  telmisartan-treated  cells  by
staining  the  cells  with  MitoTracker  Red  CMXRos,  which
accumulates  in  active  mitochondria  (Figure  6B).  These
results  imply  that  in  the  presence  of  telmisartan,  glucose  is
imported into cells, but not used for glycolysis and this could
cause mitochondrial fragmentation and ROS release.
Telmisartan has synergistic effects with
vemurafenib in vitro
In  melanoma  patients  treated  with  the  BRAF  inhibitor








































































































































































Figure 4   Telmisartan induces generation of reactive oxygen species in melanoma cells. Representative graph (A) and quantification (B) of
DCFDA fluorescence as a measure of ROS generation in A375 cells after 24 h treatment with 50 μM telmisartan, 100 μm pioglitazone or 100
μm losartan. Values represent mean ± SD, **P < 0.01, One way ANOVA, n = 3. (C) Flow cytometric analysis of phospho-p38 in A375 cells
after 24 h treatment with 50 μM telmisartan. Values represent mean ± SD, **P < 0.01, unpaired t-test, n = 3. (D) Telmisartan-induced ROS
generation in A375 cells in the presence of reduced 1 mM glutathione (GSH), 10 mM N-acetyl cysteine (NAC) or 100 μM apocynin (APO).
Values represent mean ± SD, individual comparisons by unpaired t-test, n = 3. (E) Telmisartan-induced ROS generation in HTB140 cells in
presence of 10 mM NAC. Values represent mean ± SD, individual comparisons by unpaired t-test, *P < 0.05, n = 3. (F) Representative
graphs of measurement of mitochondrial potential of A375 cells by flow cytometry of Rhodamine123 in cells treated with 50 μM telmisartan
or 100 μM pioglitazone, n = 2.
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vemurafenib, there is a lack of durable response, and in vitro,
there  is  incomplete  apoptosis36.  In  recent  years,  targeting
mitochondrial  function  to  improve  the  response  to
BRAF/MAPK inhibitors  and overcome resistance  has  shown
promising  results37-39.  Therefore,  we  tested  whether




































































































































































Figure 5   Telmisartan alters melanoma cell bioenergetics. (A) Representative graphs (i) and quantification (ii) of 2-NBDG uptake in A375
cells after 1 h or 24 h treatment with 50 μM telmisartan or pioglitazone, measured by flow cytometry. Values represent mean ± SD, One-
way ANOVA, **P < 0.01, n = 3. Glucose consumption in (B) A375 cells and (E) HTB140 cells after 24 h treatment with 50 μM telmisartan or
pioglitazone. Values represent mean ± SD, * P < 0.05, ** P < 0.01, ***P < 0.001, individual comparisons by unpaired t-test, n = 3. Lactate
excretion in (C)  A375 cells  and (F)  HTB140 cells  after  treatment with 50 μM telmisartan or  pioglitazone,  measured in extracellular
acidification assay, where fluorescence signal correlates with lactate production, n = 2, linear regression analysis. (D) MTT viability assay of
A375 cells cultured in regular RPMI (11 mM glucose) or glucose enriched (25 mM) RPMI in the presence of 50 μM telmisartan, 5 mM 2DG or
the combination. ** P < 0.0049, n = 3 in unpaired t-test.
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efficacy of vemurafenib. To assess the cytotoxic effects of the
drug  combinations,  we  used  the  Chou-Talalay  model40,
which requires drugs to be administered at a fixed dose ratio.
We treated A375 cells with a combination of telmisartan and
vemurafenib in a 5 × 5 dose matrix, such that the telmisartan
IC50 to  vemurafenib  IC50 ratio  was  83:1,  and  measured  the
resultant  cell  viabilities  by  the  MTT  assay  (Figure  7A).
Isobologram  analysis  of  the  drug  combination  treatment  at
low  concentrations  and  concentrations  up  to  the  IC50 value
revealed  synergism  (Figure  7C and  7D ,  CI  =  0.325  to  CI  =
0.776);  however,  at  high  concentrations,  slight  antagonism
was  observed  (Figure  7B,  CI  =  1.04)  (Table  1).  Indeed,  the
addition of  25  μ M  telmisartan  (½IC50)  to  vemurafenib
increased  apoptosis  in  vemurafenib-treated  cells  (Figure  7E
representative  graphs  after  72  h  of  treatment  and Figure  7F
quantification).  It  has  been  reported  that  the  inhibition  of
BRAF  signaling  leads  to  the  fusion  of  mitochondrial
networks41,  with  an  increase  in  the  mitochondrial  length42.
To  investigate  the  possible  mechanism  of  the  observed
synergy,  we  examined  the  mitochondrial  morphology  in
A375  cells.  Telmisartan  prevented  the  formation  of
mitochondrial  filaments  in  vemurafenib-treated  cells  and
Control 50 μM pioglitazone 50 μM telmisartan









Figure 6   Telmisartan induces mitochondrial fragmentation. (A) Immunocytochemistry of TOM20 (green) marker for mitochondria in
telmisartan- or pioglitazone-treated A375 and HTB140 cells. Nuclei-DAPI-blue, scale bar 20 μm. Arrowheads point to the fragmented
mitochondria. (B) MitoTracker Red CMXRos staining of the untreated and telmisartan treated A375 and HTB140 cells. White arrowheads
point to the mitochondria that are presented in the zoomed-in inset (middle panel). Scale bar 20 μm.
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Figure 7   Telmisartan has synergistic effects with vemurafenib in vitro. (A) 5 × 5 dose matrix for vemurafenib x telmisartan combination in
A375 cells. Percent growth inhibition is visualized using a color scale. The data in matrix are average of three experiments. Isobologram
analysis for the combination effect of (B) ED90 (C) ED75 and (D) ED50, single doses of vemurafenib and telmisartan were used to draw the
line of additivity. Green triangles represent single doses needed for the combination effect ED. Representative graphs (E) and quantification
of three independent experiments (F) for apoptosis in A375 cells treated with combination of vemurafenib and telmisartan. Two-way
ANOVA, ****P < 0.0001. (G) MitoTracker Red CMXRos staining for mitochondria in telmisartan-, vemurafenib- or the combination-treated
A375 cells. Arrowheads point to the fragmented mitochondria. Scale bar 20 μm.
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induced  fragmentation,  similar  to  the  treatment  with
telmisartan alone (Figure 7G and Supplementary Figure S1).
Telmisartan is effective in vemurafenib-
resistant melanoma cells
As  switching  to  oxidative  metabolism  in  BRAF  V600E
mutant  vemurafenib-resistant  tumors  is  one  of  the  main
causes of targeted drug resistance, we examined whether cells
from the vemurafenib-resistant BRAF V600E mutant cell line
A375  are  sensitive  to  telmisartan.  We  generated  the  A375R
cell  line  by  continuously  growing  parental  A375  cells  in  the
presence  of  increasing  concentrations  of  vemurafenib,
starting  from  IC10,  until  reaching  2  ×  IC50 of  the  parental
A375 (1 μM vemurafenib) with no detectable cell death. The
resistant  cell  line  had  a  shorter  doubling  time  (18  h,
compared  to  24  h  for  the  parental  cell  line, Figure  8A)  and
five  times  higher  IC50 value  for  vemurafenib,  as  seen  in  the
MTT test  (3  μM, compared  to  0.6  μM  for  the  parental  cell
line, Figure 8B). Analysis of the cell cycle showed that unlike
the parental  cell  line,  which  in  response  to  0.5  μM
vemurafenib  showed  an  increase  in  the  fraction  of  sub  G1
phase cells (late apoptosis) and a decrease in the fraction of S
and  G2/M  phase  cells  after  72  h  of  treatment,  the  cell  cycle
distribution in  A375R cells  was  not  affected by vemurafenib
treatment (Figure 8C). Nevertheless, the A375R cell line still
responded to telmisartan, with an IC50 of 35 μM, as observed
in  the  MTT  test  (Figure  8D),  and  showed  the  induction  of
ROS  generation  in  the  presence  of  telmisartan  (Figure  8E).
In addition, treatment with telmisartan sensitized the cells to
vemurafenib, as shown by the increased apoptotic fraction of
A375R cells  treated  with  25  μ M telmisartan  and  0.5  μM
vemurafenib,  compared  to  the  treatment  with  either  agent
alone (Figure 8F quantification and Figure 8G representative
graphs  of  Annexin/PI  assay).  These  results  imply  that
telmisartan  may  revert  the  vemurafenib  resistance  acquired
by melanoma cells.
Discussion
While metastatic melanoma remains an incurable disease, in
recent  years,  immune-checkpoint  inhibitors  and  targeted
drugs  have  improved  the  progression-free  and  overall
survival  of  melanoma  patients43.  Unfortunately,  most
responses  to  targeted  therapy  are  transient  due  to  the
development  of  secondary  mutations,  upregulation  of
alternative  signaling  cascades,  and metabolic  adaptations.  In
this  study,  we  tested  the  effects  of  telmisartan,  which  is  an
AGTR1 inhibitor and partial  agonist  of  the PPARγ receptor,
on  melanoma  cell  viability.  We  found  that  the  mRNA
expression for both receptors is present in human melanoma
samples  and  melanoma  cell  lines,  with  a  trend  of
downregulation,  compared  to  uninvolved  skin.  Losartan,  a
pure  AGTR1  inhibitor,  had  no  effects  on  cell  viability;
however, the effects of telmisartan also did not correlate with
the PPARγ  receptor  expression.  Various  thiazolidinediones
(PPARγ agonists) have been reported to inhibit the activity of
OXPHOS  complexes44 independently  of  the  PPARγ
receptor45.  In  our  study,  telmisartan induced melanoma cell
apoptosis,  more  efficiently  in  cells  from  BRAF  mutant
melanoma  cell  lines,  which  require  constant  glucose  and
glutamine sources for rapid proliferation and growth46.  This
implied that the cytotoxic effect of telmisartan is metabolism
dependent.  Melanoma  cells  have  intrinsically  high  levels  of
oxidative  stress  due  to  their  accelerated  metabolism,  which
renders  them  more  susceptible  to  oxidative  stress-induced
cell  death  than  normal  cells47,48.  We  found  that  telmisartan
induces  the  generation of  ROS and alters  the  mitochondrial
polarization  and  morphology.  Telmisartan  increased  the
glucose uptake, but failed to induce the increase in glycolysis.
In  addition  to  its  role  in  energy  production,  glucose
metabolism leads to the formation of pyruvate and NADPH,
both  of  which  function  in  the  cellular  detoxification  of
hydroperoxides.  When  glucose-stimulated  ROS  production,
leading  to  further  glucose  uptake,  is  not  adequately
counterbalanced  by  (glucose-stimulated)  ROS  scavenging
systems,  a  toxic  cycle  is  triggered,  ultimately  leading  to  cell
death30, which is what we observed in the telmisartan-treated
melanoma  cells.  We  hypothesize  that  the  pro-apoptotic
effects  of  telmisartan  were  PPARγ receptor-independent,  as
they did not  correlate  with the PPARγ  expression levels,  but
were  metabolic  phenotype-dependent,  as  the  effects  of
telmisartan  did  correlate  with  the  BRAF  status.  Consistent
with  this,  the  combination  of  telmisartan  and  vemurafenib
Table 1   Isobologram analysis of the drug combination treatment
Substance
Drug concentration
I II III IV
Tel 61.08± 56.89± 40.32± 29.35±
Vem 59.48± 54.54± 41.99± 36.89±
Mixture 69.64± 69.01± 66.55± 61.08±
CI 1.104 0.767 0.456 0.325
Interaction - ++ +++ +++
Interaction: +++, synergism; ++ moderate synergism; -, slight
antagonism
Tel (μM): I = 75; II = 50; III = 25; IV = 12.5
Vem (μM): I = 0.9; II = 0.6; III = 0.3; IV = 0.15
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had synergistic effects in vitro.  The addition of a low dose of
telmisartan  increased  apoptosis  in  vemurafenib-treated  cells
and  induced  mitochondrial  fragmentation.  Synergy  with
vemurafenib  could  be  argued  by  the  prevention  of
mitochondrial  fusion  that  happens  upon  vemurafenib
treatment  as  a  strategy  to  compensate  for  the  inhibition  of
glycolysis39.  The  proposed  mechanism  of  telmisartan  action
is  depicted  in Supplementary  Figure  S2.  In  addition,
telmisartan  treatment  was  effective  in  vemurafenib-resistant
A375R  cells;  more  importantly,  telmisartan  treatment
sensitized these cells to vemurafenib.
Specific PPARγ agonists have been previously reported to
have  anti-melanoma  effects10,  with  these  effects  being
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Figure 8   Telmisartan is effective in vemurafenib-resistant melanoma cells. (A) Growth rates and (B) vemurafenib sensitivity of A375
parental and A375R vemurafenib resistant cell line. Non-linear fit, Two-way ANOVA, P = 0.005 for the 72 h time point in growth curves,
****P < 0.0001 for sensitivity across all values. (C) Cell cycle distribution of A375 parental and A375R cells after 72 h treatment with 0.5 μM
vemurafenib, n = 3. (D) Percent viability of A375 and A375R cells after 72 h treatment with telmisartan, presented as log (inhibitor) vs.
normalized response. (E) Relative ROS (DCFDA) in A375R cells after 24 h treatment with 50 μM telmisartan, values represent mean ± SD, *P
< 0.05, t-test, n = 3. (F) Quantification and (G) representative graphs of apoptosis assay in A375R cells after 72 h treatment with telmisartan,
vemurafenib or the combination. Values represent mean ± SD, Two-way ANOVA, ***P < 0.001, n = 3.
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to act at the mitochondrial level, independent of the PPARγ
protein  level,  when  administered  at  higher  doses12.
Unfortunately,  clinical  monotherapy  trials  with  PPARγ
agonists were hindered by studies showing pro-angiogenic
and  pro-tumorigenic  effects  of  direct  PPARγ  agonists50.
However, the extent of the PPARγ-mediated transcription
stimulated by telmisartan is one-third of that stimulated by
glitazones51, and the binding of telmisartan to PPARγ results
in  a  different  gene  expression  profile52.  In  our  study,
telmisartan showed pro-apoptotic effects at lower doses when
compared  to  the  direct  agonist  pioglitazone,  and  with  a
distinct mechanism. In healthy individuals, the maximum
steady-state plasma level of telmisartan after the oral intake
of 320 mg of telmisartan is 20 μM in males53 and the plasma
concentrations of telmisartan are generally 2–3 times higher
in  females  than  in  males54.  Therefore,  effective  doses  of
telmisartan  examined  in  vitro  can  be  administered  to
patients. Our findings provide a rationale for retrospective
studies aiming to determine whether telmisartan influences
the  progression,  therapy  outcome,  and  mortality  rate  in
melanoma patients.
Acknowledgements
This work was supported by grants from the Serbian Ministry
for Education, Science and Technology Development (Grant
No.  III41026  and  175053).  We  would  like  to  thank  Suada
Murtezani,  Marija Vidosavljević,  Nemanja Milosavljević and
Nevena Kardum for technical assistance.
Conflict of interest statement
No potential conflicts of interest are disclosed.
References
Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and
immunotherapies: optimizing outcomes in melanoma. Nat Rev
Clin Oncol. 2017; 14: 463-82.
1.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4
therapies in cancer: mechanisms of action, efficacy, and limitations.
Front Oncol. 2018; 8: 86.
2.
Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu JX, Naraev
N, et al. Mechanisms of resistance to BRAF and MEK inhibitors
and clinical update of US Food and Drug Administration-approved
targeted therapy in advanced melanoma. Onco Targets Ther. 2018;
11: 7095-107.
3.
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J,
Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF
4.
inhibition is mediated by a network of transcriptional regulators of
glycolysis. Cancer Discov. 2014; 4: 423-33.
Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe
GC, et al. Oncogenic BRAF regulates oxidative metabolism via
PGC1α and MITF. Cancer Cell. 2013; 23: 302-15.
5.
Abildgaard C, Guldberg P. Molecular drivers of cellular metabolic
reprogramming in melanoma. Trends Mol Med. 2015; 21: 164-71.
6.
Shim JS, Liu JO. Recent advances in drug repositioning for the
discovery of new anticancer drugs. Int J Biol Sci. 2014; 10: 654-63.
7.
Otake AH, Mattar AL, Freitas HC, Machado CML, Nonogaki S,
Fujihara CK, et al. Inhibition of angiotensin II receptor 1 limits
tumor-associated angiogenesis and attenuates growth of murine
melanoma. Cancer Chemother Pharmacol. 2010; 66: 79-87.
8.
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome
proliferator-activated receptors: from genes to physiology. Recent
Prog Horm Res. 2001; 56: 239-63.
9.
Mössner R, Schulz U, Krüger U, Neumann C, Reich K, Middel P,
et al. Agonists of peroxisome proliferator-activated receptor γ
inhibit cell growth in malignant melanoma. J Invest Dermatol.
2002; 119: 576-82.
10.
Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P,
Schicher N, et al. Proteome analysis identified the PPARγ ligand
15d-PGJ2 as a novel drug inhibiting melanoma progression and
interfering with tumor-stroma interaction. PLoS One. 2012; 7:
e46103.
11.
Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne
JP, et al. In vitro and in vivo anti-melanoma effects of ciglitazone. J
Invest Dermatol. 2009; 129: 1208-18.
12.
Zhang SL, Wang YY. Telmisartan inhibits NSCLC A549 cell
proliferation and migration by regulating the PI3K/AKT signaling
pathway. Oncol Lett. 2018; 15: 5859-64.
13.
Rasheduzzaman M, Moon JH, Lee JH, Nazim UM, Park SY.
Telmisartan generates ROS-dependent upregulation of death
receptor 5 to sensitize TRAIL in lung cancer via inhibition of
autophagy flux. Int J Biochem Cell Biol. 2018; 102: 20-30.
14.
Pu ZC, Zhu M, Kong DF. Telmisartan prevents proliferation and
promotes apoptosis of human ovarian cancer cells through
upregulating PPARγ and downregulating MMP-9 expression. Mol
Med Rep. 2016; 13: 555-9.
15.
Oura K, Tadokoro T, Fujihara S, Morishita A, Chiyo T, Samukawa
E, et al. Telmisartan inhibits hepatocellular carcinoma cell
proliferation in vitro by inducing cell cycle arrest. Oncol Rep. 2017;
38: 2825-35.
16.
Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K,
et al. The angiotensin II type 1 receptor antagonist telmisartan
inhibits cell proliferation and tumor growth of esophageal
adenocarcinoma via the AMPKα/mTOR pathway in vitro and in
vivo. Oncotarget. 2017; 8: 8536-49.
17.
Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A.
Extrapulmonary, tissue-specific metastasis formation in nude mice
injected with FEMX-I human melanoma cells. Cancer Res. 1988;
18.
Cancer Biol Med Vol 16, No 2 May 2019 261
48: 4382-8.
Timenetsky J, Santos LM, Buzinhani M, Mettifogo E. Detection of
multiple mycoplasma infection in cell cultures by PCR. Braz J Med
Biol Res. 2006; 39: 907-14.
19.
Zou CH, Wang YJ, Shen ZF. 2-NBDG as a fluorescent indicator for
direct glucose uptake measurement. J Biochem Biophys Methods.
2005; 64: 207-15.
20.
Chou TC, Talalay P. Quantitative analysis of dose-effect
relationships: the combined effects of multiple drugs or enzyme
inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
21.
Talantov D, Mazumder A, Yu JX, Briggs T, Jiang YQ, Backus J,
et al. Novel genes associated with malignant melanoma but not
benign melanocytic lesions. Clin Cancer Res. 2005; 11: 7234-42.
22.
Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu
M, et al. Integrative genome comparison of primary and metastatic
melanomas. PLoS One. 2010; 5: e10770.
23.
Riker AI, Enkemann SA, Fodstad O, Liu SH, Ren SP, Morris C,
et al. The gene expression profiles of primary and metastatic
melanoma yields a transition point of tumor progression and
metastasis. BMC Med Genomics. 2008; 1: 13.
24.
Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al.
Gene expression changes in an animal melanoma model correlate
with aggressiveness of human melanoma metastases. Mol Cancer
Res. 2008; 6: 760-9.
25.
Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL,
Adams S, et al. Immune profile and mitotic index of metastatic
melanoma lesions enhance clinical staging in predicting patient
survival. Proc Natl Acad Sci USA. 2009; 106: 20429-34.
26.
Cheng XL, Holenya P, Can SZ, Alborzinia H, Rubbiani R, Ott I,
et al. A TrxR inhibiting gold(I) NHC complex induces apoptosis
through ASK1-p38-MAPK signaling in pancreatic cancer cells. Mol
Cancer. 2014; 13: 221.
27.
Cash TP, Pan Y, Simon MC. Reactive oxygen species and cellular
oxygen sensing. Free Radic Biol Med. 2007; 43: 1219-25.
28.
Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J,
Wieckowski MR. Relation between mitochondrial membrane
potential and ROS formation. Methods Mol Biol. 2012; 810:
183-205.
29.
Liemburg-Apers DC, Willems PHGM, Koopman WJH, Grefte S.
Interactions between mitochondrial reactive oxygen species and
cellular glucose metabolism. Arch Toxicol. 2015; 89: 1209-26.
30.
Kim HI, Ahn YH. Role of peroxisome proliferator-activated
receptor-γ in the glucose-sensing apparatus of liver and β-cells.
Diabetes. 2004; 53 Suppl 1: S60-5.
31.
El-Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by
pioglitazone in cultured muscle cells. Metabolism. 1994; 43: 953-8.
32.
Gottfried E, Rogenhofer S, Waibel H, Kunz-Schughart LA, Reichle
A, Wehrstein M, et al. Pioglitazone modulates tumor cell
metabolism and proliferation in multicellular tumor spheroids.
Cancer Chemother Pharmacol. 2011; 67: 117-26.
33.
Yu TZ, Robotham JL, Yoon Y. Increased production of reactive34.
oxygen species in hyperglycemic conditions requires dynamic
change of mitochondrial morphology. Proc Natl Acad Sci USA.
2006; 103: 2653-8.
Yu TZ, Jhun BS, Yoon Y. High-glucose stimulation increases
reactive oxygen species production through the calcium and
mitogen-activated protein kinase-mediated activation of
mitochondrial fission. Antioxid Redox Signal. 2011; 14: 425-37.
35.
Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S,
Windhövel S, et al. Vemurafenib induces senescence features in
melanoma cells. J Invest Dermatol. 2013; 133: 1601-9.
36.
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, et al.
Targeting mitochondrial biogenesis to overcome drug resistance to
MAPK inhibitors. J Clin Invest. 2016; 126: 1834-56.
37.
Strohecker AM, White E. Targeting mitochondrial metabolism by
inhibiting autophagy in BRAF-driven cancers. Cancer Discov. 2014;
4: 766-72.
38.
Corazao-Rozas P, Guerreschi P, André F, Gabert PE, Lancel S,
Dekiouk S, et al. Mitochondrial oxidative phosphorylation controls
cancer cell's life and death decisions upon exposure to MAPK
inhibitors. Oncotarget. 2016; 7: 39473-85.
39.
Chou TC. Drug combination studies and their synergy
quantification using the Chou-Talalay method. Cancer Res. 2010;
70: 440-6.
40.
Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Asciolla JJ, Yao
JL, et al. Mitochondrial division is requisite to RAS-induced
transformation and targeted by oncogenic MAPK pathway
inhibitors. Mol Cell. 2015; 57: 521-36.
41.
Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, et al.
Dysregulation of mitochondrial dynamics proteins are a targetable
feature of human tumors. Nat Commun. 2018; 9: 1677.
42.
Pasquali S, Kefford R, Sileni VC, Nitti D, Rossi CR, Pilati P, et al.
Systemic treatments for metastatic cutaneous melanoma. Cochrane
Database Syst Rev. 2018; 2: CD011123..
43.
Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y.
Mitochondrial impairment by PPAR agonists and statins identified
via immunocaptured OXPHOS complex activities and respiration.
Toxicol Appl Pharmacol. 2007; 223: 277-87.
44.
Scatena R, Bottoni P, Giardina B. Mitochondria, PPARs, and
cancer: is receptor-independent action of PPAR agonists a key?
PPAR Res. 2008; 2008: 256251.
45.
Lakhter AJ, Hamilton J, Konger RL, Brustovetsky N, Broxmeyer
HE, Naidu SR. Glucose-independent acetate metabolism promotes
melanoma cell survival and tumor growth. J Biol Chem. 2016; 291:
21869-79.
46.
Hambright HG, Meng P, Kumar AP, Ghosh R. Inhibition of
PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival
of melanoma cells. Oncotarget. 2015; 6: 7195-208.
47.
Nogueira V, Hay N. Molecular pathways: reactive oxygen species
homeostasis in cancer cells and implications for cancer therapy.
Clin Cancer Res. 2013; 19: 4309-14.
48.
Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle49.
262 Grahovac et al. Telmisartan induces melanoma cell apoptosis
GM, et al. PPARγ agonists attenuate proliferation and modulate
Wnt/β-catenin signalling in melanoma cells. Int J Biochem Cell
Biol. 2009; 41: 844-52.
Veliceasa D, Schulze-Hoëpfner FT, Volpert OV. PPARgamma and
agonists against cancer: rational design of complementation
treatments. PPAR Res. 2008; 2008: 945275.
50.
Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu
A, et al. A selective peroxisome proliferator-activated receptor-γ
modulator, telmisartan, binds to the receptor in a different fashion
from thiazolidinediones. Endocrinology. 2009; 150: 862-70.
51.
Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S,
et al. Molecular characterization of new selective peroxisome
proliferator-activated receptor γ modulators with angiotensin
receptor blocking activity. Diabetes. 2005; 54: 3442-52.
52.
Stangier JC, Su CAPF, Roth W. Pharmacokinetics of orally and53.
intravenously administered telmisartan in healthy young and
elderly volunteers and in hypertensive patients. J Int Med Res. 2000;
28: 149-67.
Cabaleiro T, Román M, Ochoa D, Talegón M, Prieto-Pérez R,
Wojnicz A, et al. Evaluation of the relationship between sex,
polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of
angiotensin receptor blockers. Drug Metab Dispos. 2013; 41: 224-9.
54.
Cite  this  article  as:  Grahovac  J,  Srdić-Rajić  T,  Francisco  Santibañez  J,
Pavlović  M,  Čavić  M,  Radulović  S.  Telmisartan  induces  melanoma  cell
apoptosis  and  synergizes  with  vemurafenib  in  vitro  by  altering  cell
bioenergetics. Cancer Biol Med. 2019; 16: 247-63. doi: 10.20892/j.issn.2095-
3941.2018.0375
Cancer Biol Med Vol 16, No 2 May 2019 263
Supplementary materials
 
Control Telmisartan Vemurafenib Telmisartan + Vemurafenib
TOM20 DAPI
 
Figure S1   Immunocytochemistry of TOM20 (green) marker for mitochondria in telmisartan-, vemurafenib- or the combination-treated













Figure S2   Schematic of the proposed mechanism of telmisartan
action.
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